NASDAQ:NTLA

Intellia Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy NTLA

*Your capital is at risk

$13.02

-1.20 (-8.41%)

At Close: Jul 13, 2026

Intellia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 32.39. In total, the insiders bought 2.23M and sold 214.29K NTLA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	32.39
● Buy	2.23M shares
● Sell	214.29K shares
69% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Jul 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 32.39. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 02, 2026 Sell	Common Stock S-Sale	Dulac Edward J Iii EVP, Chief Financial Officer	C-Suite Officer	4 677 Value: $84.2K
Jul 01, 2026 Sell	Common Stock S-Sale	Dube Michael P Vp, Chief Accounting Officer	Officer	2 641 Value: $44.3K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Bhanji Muna Director	Director	13 300 Value: $171.4K
Jun 09, 2026 Buy	Common Stock A-Award	Bhanji Muna Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Chase William J Director	Director	13 300 Value: $171.4K
Jun 09, 2026 Buy	Common Stock A-Award	Chase William J Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Common Stock A-Award	Verwiel Frank Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Verwiel Frank Director	Director	13 300 Value: $171.4K
Jun 09, 2026 Buy	Common Stock A-Award	Keresty Georgia Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Keresty Georgia Director	Director	13 300 Value: $171.4K
Jun 09, 2026 Buy	Common Stock A-Award	Goodman Jesse Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Goodman Jesse Director	Director	13 300 Value: $171.4K
Jun 09, 2026 Buy	Common Stock A-Award	Goff Brian Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Goff Brian Director	Director	13 300 Value: $171.4K
Jun 09, 2026 Buy	Common Stock A-Award	Cohen Fred E Director	Director	9 200 Value: $118.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Cohen Fred E Director	Director	13 300 Value: $171.4K
Mar 02, 2026 Sell	Common Stock S-Sale	Basta James EVP, General Counsel	Officer	1 211 Value: $16.7K
Mar 02, 2026 Sell	Common Stock S-Sale	Clark Eliana EVP, Chief Technical Officer	Officer	607 Value: $8K
Mar 01, 2026 Buy	Common Stock A-Award	Schultes Birgit C EVP, Chief Scientific Officer	Officer	39 200 Value: $510.4K
Mar 01, 2026 Buy	Common Stock A-Award	Leonard John M President And CEO	CEO / President	156 400 Value: $2.04M
Mar 01, 2026 Buy	Stock Option (right to buy) A-Award	Leonard John M President And CEO	CEO / President	225 400 Value: $3.11M
Mar 01, 2026 Buy	Common Stock A-Award	Basta James EVP, General Counsel	Officer	46 080 Value: $600.0K
Mar 01, 2026 Buy	Stock Option (right to buy) A-Award	Lebwohl David EVP, Chief Medical Officer	Officer	14 204 Value: $195.7K
Mar 01, 2026 Buy	Common Stock A-Award	Dulac Edward J Iii EVP, Chief Financial Officer	C-Suite Officer	61 280 Value: $797.9K
Mar 01, 2026 Buy	Stock Option (right to buy) A-Award	Basta James EVP, General Counsel	Officer	65 829 Value: $907.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INTELLIA THERAPEUTICS INC

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...

Read Full Profile Here